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Abstract
There are conﬂicting reports on the adverse effects of erythropoietin (EPO) for the management of cancer-associated
anemia. The recognition that erythropoietin receptors (EPORs) are expressed outside the erythroid lineage and
concerns that erythropoiesis-stimulating agents (ESAs) may cause tumors to grow and increase the risk of venous
thromboembolism have resulted in substantially fewer cancer patients receiving ESA therapy to manage
myelosuppressive chemotherapy. In this study, we found that EPO suppresses p53-dependent apoptosis induced by
genotoxic (daunorubicin, doxorubicin, and γ-radiation) and non-genotoxic (nutlin-3a) agents and induces a
senescence-like state in myeloid leukemia cells. EPO interferes with stress-dependent Mdm2 downregulation and
leads to the destabilization of p53 protein. EPO selectively modulates the expression of p53 target genes in response
to DNA damage preventing the induction of a number of noncoding RNAs (ncRNAs) previously associated with p53-
dependent apoptosis. EPO also enhances the expression of the cyclin-dependent kinase inhibitor p21WAF1 and
promotes recruitment of p53 to the p21 promoter. In addition, EPO antagonizes Mcl-1 protein degradation in
daunorubicin-treated cells. Hence, EPO signaling targets Mcl-1 expression and the p53-Mdm2 network to promote
tumor cell survival.
Introduction
The p53 tumor suppressor protein coordinates the
cellular response to stress in mammalian cells. Basal levels
of p53 are low primarily due to interaction with the
Mdm2 E3 ubiquitin ligase that mediates degradation of
p53. In response to diverse stress signals, including DNA
damage, telomere shortening, and oncogene-induced
replicative stress, p53 protein undergoes extensive post-
translational modiﬁcation resulting in increased stability
and activity1. Once activated, p53 protein functions pri-
marily as a sequence-speciﬁc DNA binding transcription
factor to regulate the expression of genes and noncoding
RNAs (ncRNAs) that collectively contribute to p53-
dependent cellular responses including apoptosis, cell
cycle arrest, senescence, and DNA repair. The divergent
biological outcomes mediated by p53 are thought to be
due to differential transcription of p53 target genes2,3. The
targeting of p53 to different promoters is inﬂuenced by
many factors, including p53 protein levels, posttransla-
tional modiﬁcations of p53 that regulate its interaction
with various transcriptional coactivators, the speciﬁc p53
response element sequence, and the intrinsic properties of
diverse p53 core promoters that affect binding afﬁnity and
p53 recruitment1–5.
Erythropoietin (EPO), a glycoprotein produced in the
kidney under hypoxic conditions, functions as the prin-
cipal regulator of red blood cell production by controlling
the proliferation, survival, and differentiation of immature
erythroid progenitors into mature red cells. Upon binding
EPO, the EPO receptor (EPOR) undergoes dimerization
that in turn activates the receptor-associated tyrosine
kinase, Janus Kinase 2 (JAK2). Activated JAK2 phos-
phorylates tyrosine residues found on the cytosolic
domain of the EPOR leading to the recruitment of
© The Author(s) 2019
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Samuel Benchimol (benchimo@yorku.ca)
1Department of Biology, York University, Toronto, ON M3J 1P3, Canada
Edited by A. Oberst


































downstream effectors, including PI3K, GRB2, and the
STAT family members6–9.
Previously, we reported that EPO protects DP16.1/p53ts
cells from p53-dependent apoptosis10. DP16.1/p53ts cells
were derived by stable expression of a temperature-
sensitive (ts) p53 allele (A135V) in the p53-null, spleen
focus-forming virus-transformed, mouse erythroleukemia
cell line DP16.1. DP16.1/p53ts cells grow well at 37 °C and
undergo p53-dependent apoptosis when p53 is activated
at 32 °C. At 32 °C, in the presence of EPO, DP16.1/p53ts
cells remain viable and arrest in the G1 phase of the cell
cycle10. Numerous extracellular cytokines, including EPO,
IL3, IL6, macrophage migration inhibitory factor (MIF)
and stem cell factor (SCF), have been shown to prevent
p53-dependent apoptosis11–18. The common ability of
survival-promoting cytokines to suppress p53-induced
apoptosis may reﬂect a physiological mechanism through
which p53-positive tumors gain resistance to apoptosis-
inducing anticancer agents19.
Erythropoiesis-stimulating agents (ESAs), including
EPO, were used routinely to treat anemia in cancer
patients receiving myelosuppressive chemotherapy. ESAs
increase red blood cell production in bone marrow by
activating the EPOR on erythroid progenitor cells result-
ing in a decreased need for red blood cell transfusion.
EPO and its receptor, however, are expressed in various
tissues outside the hematopoietic system with tissue
protective effects of EPO demonstrated initially in the
brain, heart and kidney20,21. In 2003, two studies found
that patients with metastatic breast cancer and patients
with head and neck cancer who received recombinant
human EPO (rHuEPO) in combination with chemother-
apy or radiation therapy to manage cancer-associated
anemia exhibited higher mortality compared with patient
groups who received a placebo22,23. Subsequent clinical
studies reported that the use of ESAs to treat cancer
patients reduced overall survival possibly related to an
increased risk of thromboembolism and increased tumor
progression24–30. The ongoing concern that ESAs may be
linked to increased mortality risks has resulted in sub-
stantially fewer cancer patients receiving ESA therapy to
manage myelosuppressive chemotherapy31 and remains
highly controversial32–34.
Here we examine the ability of EPO to protect DA3/
EPOR murine leukemia cells from stress-induced apop-
tosis. These EPOR-expressing cells express wild-type p53
and undergo apoptosis in response to genotoxic stress.
They provide an experimental model to investigate the
effect of EPO on cancer cells exposed to chemotherapy.
We demonstrate that EPO destabilizes p53 protein,
selectively modulates p53-target gene expression, increa-
ses Mcl-1 protein expression and promotes a senescence-




DA3/EPOR murine leukemic cells35 were maintained at
37 °C with 5% CO2 in RPMI 1640 media supplemented
with 10% fetal bovine serum (FBS) and 1 U/ml recombi-
nant human erythropoietin (EPO). OCI-M1 human acute
myeloid leukemic cells36 were maintained at 37 °C with
5% CO2 in α-MEM with 10% FBS.
Drug treatment
DA3/EPOR cells were washed with RPMI 1640 con-
taining 10% FBS and incubated at 37 °C for 1 h without
EPO. Cells are then treated with daunorubicin (DNR)
(0.25 µM) or doxorubicin (Dox) (200 ng/ml), in the
absence or presence of rHuEPO (1 U/ml). Cell viability
was assessed by staining with trypan blue. MG-132 was
purchased from Sigma-Aldrich and added directly to cells
in culture media at a ﬁnal concentration of 5 μM. Nutlin-
3a was purchased from Santa Cruz (sc-45061).
Cell cycle analysis
Cells were pelleted and washed with phosphate buf-
fered saline (PBS) and ﬁxed in cold 75% ethanol before
freezing at −20 °C until use. Fixed cells were washed
with cold PBS at 4 °C and suspended in Staining Buffer
(0.2% Triton X-100, 1 mM ethylenediaminetetraacetic
acid [EDTA], in PBS) followed by incubation with
RNaseA (100 µg/ml, ThermoScientiﬁc) at 37 °C for
30 min. Cells were stained with 50 µg/ml propidium
iodide for 1 h. Propidium iodide ﬂuorescence was mea-
sured using a BD FACSCalibur ﬂow cytometer (Becton
Dickinson) and data analysis was performed using the
BD CellQuest Pro software.
Nucleofection
Nucleofection was performed according to the manu-
facturer’s instructions (Lonza). DA3/EPOR cells (2×106)
were suspended in Cell Line Nucleofector Solution V and
combined with 2 µg of plasmid vector comprised of a 9:1
ratio of pCMV/p53DD plasmid37 to pSUPER-puromycin
or PCDNA3 (Invitrogen Life Technology). Cells were
pulsed with the Nucleofector X-001 program using a
Nucleofector 2b device. Pulsed cells were transferred to
prewarmed media containing 10% FBS and EPO (1 U/ml)
and allowed to recover for 48 h. Clones were selected in
puromycin (1 µg/ml, Sigma-Aldrich Canada Ltd.) over
4 weeks. p53DD expression was conﬁrmed by
immunoblotting.
Apoptosis assays
Caspase-3 activity was measured cells using the Nuc-
View 488 Caspase-3 Assay Kit according to the manu-
facturer’s instructions (Biotium, Inc.). TUNEL assay was
performed as described15.
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Northern blotting
Total RNA was isolated and RNA samples were run on
a denaturing agarose gel for coding RNAs or acrylamide
gel for ncRNAs. Hybridization of radioactive probes was
performed using standard conditions.
Western blotting
Cells were directly lysed in 1× SDS (sodium dodecyl
sulfate) lysis buffer (10% SDS, 10% glycerol, 88mM Tris-
HCl pH 6.8, in water) and boiled at 97 °C for 10min fol-
lowed by addition of 0.1% bromophenol blue and 0.1M
dithiothreitol (DTT). Total protein was separated by SDS-
polyacrylamide gel electrophoresis and transferred onto
nitrocellulose membranes followed by incubation with
primary antibodies. The antibodies to p53 included:
PAb42138, FL393 (sc-6243, Santa Cruz Biotechnology),
DO-1 (sc-126, Santa Cruz Biotechnology). Antibodies to
Mdm2 included: SMP14 (sc-965; Santa Cruz Biotechnol-
ogy), p-MDM2 (Ser166) (#3521; Cell Signaling Technol-
ogy), and HDM2-323 (sc-56154; Santa Cruz
Biotechnology). Antibodies to p21 (sc-397), JAK2 (sc-278),
pJAK2 (sc-21870), Akt-1 (sc-5298), p-Akt1 (sc-293125),
and β-actin were from Santa Cruz Biotechnology. Anti-
MCL1 antibody [Y37] (ab32087) was from Epitomics/
Abcam. Protein levels were measured using a Typhoon
Trio Plus Imager (GE Healthcare) with Cy3 and Cy5-
conjugated secondary antibodies or visualized using HRP-
conjugated secondary antibodies with enhanced chemilu-
minescence detected on ﬁlm.
Cycloheximide treatment
After treatment of cells with DNR and/or EPO, 40 µg/ml
cycloheximide (Sigma-Aldrich) was added directly to cul-
ture media to stop new protein synthesis. Cells were
harvested at different times after cycloheximide addition.
p53 and β-actin protein levels were determined by quan-
titative immunoblotting with detection on a Typhoon Trio
Plus Imager (GE Healthcare) and ImageJ software. Relative
p53 expression was normalized to β-actin levels and
plotted relative to initial p53 levels in the absence of
cycloheximide addition.
Quantitative real-time PCR
Total RNA was extracted from cells using TRIzol (Life
Technologies) according to the manufacturer’s instruc-
tions. cDNA synthesis was performed with 2 μg of total
RNA using the High Capacity RNA-to-cDNA Kit (Ther-
moFisher Scientiﬁc) and subjected to PCR using the
SsoFaster EvaGreen Supermix Kit and an Applied Bio-
systems 7500 Real-Time PCR System (ThermoFisher
Scientiﬁc) according to the manufacturer’s instructions.
Relative expression was calculated using the 2−ΔΔCt
method; Ct values were normalized to 18S RNA using the
Pfafﬂ method39. Primer efﬁciencies were evaluated and
calculated prior to use in qRT-PCR. The following oli-
gonucleotides were used as qRT-PCR primers:
Pri-miR-34a40, F 5′ CTG TGC CCT CTT GCA AAA
GG 3′, R 5′ GGA CAT TCA GGT GAG GGT CTT G 3′;
Pri-miR-34b/c, F 5′ CTC GGT TTG TAG GCA GTG
TA 3′, R 5′ TTG ATG GCA GTG GAG TTA GTG 3′;
lincRNA-p21, F 5′ CAT TCC GTC TCC AGT TCC
TAA C 3′, R 5′ CGA AGA GAC AAC GGC ACA CTT 3′;
PIDD, F 5′ TCC AGC AAG ATG TGA GCT TAT G 3′,
R 5′ GGT CAT TCC AGG TGT TAC T 3′;
PUMA, F 5′ CGG AGA CAA GAA CC AGC AAG ATG
TGA GCT TAT G 3′, R 5′ GGT CAT TCC AGG TGT
TAC T 3;
NOXA, F 5′ TCG CAA AAG AGC AGG ATG AG 3′, R
5′ CAC TTT GTC TCC AAT CCT CCG 3′;
p21, F 5′ CCA GAC ATT CAG AGC CAC AGG 3′, R
CGA AGA GAC AAC GGC ACA CTT 3′;
p53, F 5′ TAG GTA GCG ACT ACA GTT AGG G 3′, R
5′ CAT GGC AGT CAT CCA GTC TT 3′;
Mcl-1, F 5′ CAA AGA GGC TGG GAT GGG TTT-3′,
R 5′ CCC TAT TGC ACT CAC AAG GC 3′;
18S, F 5′ GTG TTG AGG AAA GCA GAC AT 3′, R 5′
CAG TCT GGG ATC TTG TAC TG 3′.
ChIP-qPCR
ChIP (chromatin immunoprecipitation) assays were
performed as described41,42 with the following modiﬁca-
tions. After formaldehyde ﬁxation, cells were pelleted at
1200 RPM at 4 °C for 8 min and washed consecutively
with: (i) ice-cold PBS (Corning), (ii) 0.25% Triton X-100,
10 mM EDTA (pH 8.0), 0.5 mM ethylene glycol tetra-
acetic acid (EGTA) (pH 7.5), 10 mM Hepes (pH 7.5)
containing protease inhibitor cocktail tablet (Roche) and
(iii) 12.5 mM NaCl, 1 mM EDTA (pH 8.0), 0.5 mM EGTA
(pH 7.5), 10 mM Hepes containing protease inhibitor
cocktail tablet. Cells were resuspended in lysis buffer
(0.15M NaCl, 25 mM Tris pH 7.5, 5 mM EDTA pH 8.0,
1% Triton X-100, 0.1% SDS, 0.5% Sodium deoxycholate,
protease inhibitor cocktail tablet) and the DNA was
sonicated to 100–400 bp using a Sonic Dismembrator
Model 500 (ThermoFisher Scientiﬁc). Sonicated cell
lysates were centrifuged at 14,000 RPM at 4 °C to pellet
cell debris. Cell extracts were precleared with prewashed
Protein-A agarose beads (Bioshop Canada Inc.) for 1 h at
4 °C.
Cell extracts containing 1 mg of protein were incubated
with 2 µg of antibody (FL393 or control IgG) at 4 °C
overnight. Forty micrograms of protein from precleared
cell lysates were used as input. Cell extracts were incu-
bated with 40 µl of prewashed Protein-A agarose beads for
1 h at 4 °C and pelleted at 4000 RPM for 5 min at 4 °C.
Protein-Agarose bead complexes were washed
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consecutively with: (i) RIPA buffer (150 mM NaCl, 50 mM
Tris pH 8.0, 0.1% SDS, 0.5% Sodium deoxycholate, 1%
NP-40, protease inhibitor cocktail), (ii) high salt solution
(0.5 M NaCl, 50 mM Tris pH 8.0, 0.1% SDS, 1% NP-40,
protease inhibitor cocktail), (iii) LiCl solution (0.25M
LiCl, 50 mM Tris pH 8.0, 0.5% Sodium deoxycholate, 1%
NP-40, protease inhibitor cocktail), and (iv) TE buffer (10
mM Tris pH 8.0, 1 mM EDTA pH 8.0, protease inhibitor
cocktail). Washed beads were then incubated with IP
elution buffer (2% SDS, 10 mM DTT, 0.1M NaHCO3) for
30min at room temperature. Eluted protein complexes
were collected and boiled at 65 °C overnight after addition
of 20 µl of 4M NaCl to reverse crosslinks.
One microliter of RNaseA (10 mg/ml) was added to
each sample and incubated at 37 °C for 30min. Twenty
microliters of 10× proteinase K buffer (0.1M Tris-HCl pH
8.0, 0.05M EDTA pH 8.0) and 20 µl of proteinase K (20
mg/ml) was added to each reaction and incubated at 42 °C
for 1 h. DNA was then separated from each reaction via
phenol-chloroform extraction and recovered by ethanol
precipitation. Samples were pelleted at 14,000 RPM for
15min at 4 °C and DNA pellets were washed with 80%
ethanol and stored in RNase/DNase free water at −80 °C
until use.
ChIP DNA samples were subjected to quantitative real-
time PCR using SsoFaster EvaGreen Supermix Kits and an
Applied Biosystems 7500 Real-Time PCR System (Ther-
moFisher Scientiﬁc) according to the manufacturer’s
instructions. Ct values were normalized to non-IP input
samples for each treatment and expressed as enrichment
compared with input. The following oligonucleotides
were used as ChIP-qPCR primers:
p21, F 5′ ACCAGCAGCAAAATCGGAGC 3′, R 5′
CCCACAGCTGGTAGTTGGGTATC 3′.
Statistical tests
Data are presented as mean values ± standard error of
the mean. P values were determined by the two-tailed
Student’s t test (to compare the means of two different
samples) or by a one-way ANOVA (to compare more
than two groups), followed by a Tukey’s multiple com-
parison test using Microsoft Excel and SPSS software.
Results
EPO suppresses DNA damage-induced apoptosis in DA3/
EPOR cells
DA3/EPOR cells were derived from the IL-3-dependent
DA3 murine leukemic cell line after transfection with
wild-type EPOR cDNA35. We have determined that these
cells express wild-type p53 based on cDNA sequence
analysis. To conﬁrm that these cells are responsive to
EPO, we measured the phosphorylation of two down-
stream effectors in the EPO signaling pathway, JAK2 and
Akt. EPO-induced phosphorylation of JAK2 (Tyr1007/
Tyr1008) and Akt (Ser473) was detected within 5 min of
treatment and increased with time (Fig. 1a). These data
indicate that DA3/EPOR cells are responsive to EPO and
may be used as an experimental model to assess how EPO
inﬂuences the response of leukemia cells to DNA-
damaging agents. DA3/EPOR cells undergo apoptosis in
response to doxorubicin (Dox), daunorubicin (DNR) and
γ-irradiation. Treatment of these cells with EPO effec-
tively prevents drug- and radiation-induced cell death
(Fig. 1b–d).
EPO promotes cell viability but not cell proliferation
DA3/EPOR cells treated with DNR and EPO for 24 h
show an accumulation of nonapoptotic cells in the G1
phase of the cell cycle (Fig. 2a). To determine if these cells
retain proliferative capacity, DA3/EPOR cells were treated
with DNR in the presence or absence of EPO for 24 h. The
cells were then washed to remove DNR and placed in
drug-free medium containing 10% FBS and EPO for 24,
48, and 72 h prior to cell counting (Fig. 2b). Similar to
cells treated with DNR in the absence of EPO for 24 h,
cells treated with DNR and EPO for 24 h did not pro-
liferate when placed in normal medium despite a large
proportion of cells remaining viable (Fig. 2b, right panel).
These ﬁndings indicate that EPO promotes survival of
DA3/EPOR cells that have undergone genotoxic stress
and that these cells are incapable of undergoing further
cell division.
DA3/EPOR cells undergo p53-dependent apoptosis in
response to DNR
To determine if DNR-induced cell death is dependent
on p53 in DA3/EPOR cells, we generated three subclones
expressing the C-terminal fragment of p53 (p53DD). This
fragment, consisting of amino acids 302–390 of p53, lacks
the DNA binding and transactivation domains of p53 and
retains the oligomerization domain. p53DD acts as a
potent trans-dominant repressor of wild-type p53 through
its ability to prevent the formation of functional p53 tet-
ramers37. Endogenous p53 protein levels are high in DA3/
EPOR cells expressing p53DD, likely resulting from the
formation of stable heterologous oligomers (Fig. S1).
DA3/EPOR-DD clones exhibit reduced apoptosis in
response to DNR compared with parental cells (Fig. S1).
EPO retained the ability to reduce apoptosis in the DNR-
treated DA3/EPOR-DD clones (Fig. S1). These data
indicate that DNR induces p53-dependent apoptosis in
DA3/EPOR cells that can be rescued by EPO.
EPO modulates the level of Mcl-1 protein in DNR-treated
cells
The prosurvival protein, Mcl-1, is associated with
resistance to anticancer therapies and its expression is
usually maintained by cytokines in hematopoietic cells. In
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addition, a number of DNA-damaging agents have been
reported to reduce Mcl-1 protein levels by promoting its
degradation43. Hence, we investigated the expression of
Mcl-1 in DA3/EPOR cells treated with DNR in the pre-
sence or absence of EPO. In untreated cells, Mcl-1
appears as a doublet by immunoblot analysis likely
resulting from proteolytic processing44. DNR treatment
reduced Mcl-1 levels and EPO restored Mcl-1 expression
(Fig. 3a). These changes in Mcl-1 protein expression were
not reﬂected by Mcl-1 mRNA levels (Fig. 3b) indicating
that DNR likely triggers Mcl-1 protein degradation and
that this process is antagonized by EPO post-
transcriptionally. The degradation of Mcl-1 is con-
sidered an important early event in apoptosis and may be
required to initiate the apoptotic response43,45. The ability
of EPO to modulate Mcl-1 protein expression likely
contributes to cell survival.
EPO promotes p53 destabilization in DNR-treated cells
Next, we measured the levels of p53 protein and mRNA
in DA3/EPOR cells treated with DNR in the presence or
absence of EPO. As expected, p53 protein levels increased
in DNR-treated cells, likely resulting from posttransla-
tional stabilization of p53 protein (Fig. 4a). Western
immunoblotting revealed a decrease in p53 protein
expression in cells treated with DNR and EPO compared
with DNR alone. The decrease was detected with a poly-
clonal antibody (FL393) and with a monoclonal antibody
(PAb421) directed to p53 (Fig. 4a). The decrease in p53
protein expression was not accompanied by any decrease
in p53 mRNA, consistent with a post-transcriptional
mechanism (Fig. 4b). Expression of the cell cycle arrest
protein p21, an important transcriptional target of p5346,
increased in response to DNR treatment and remained
elevated in cells treated with DNR and EPO (Fig. 4a).
Fig. 1 EPO suppresses DNA damage-induced apoptosis in DA3/EPOR cells. a DA3/EPOR cells were cultured in the absence of EPO for 1.5 h and
then stimulated with EPO (1 U/ml) for the times indicated. JAK2 and AKT kinase activation was determined by western blot analysis using a phospho-
speciﬁc Tyr 1007/Tyr 1008 antibody (pJAK2) and phospho-speciﬁc Ser 473 antibody (pAKT) respectively. b Cells were cultured in the absence of EPO
for 1 h followed by 6 h of treatment with Dox (200 ng/ml) or DNR (0.25 µM), with or without EPO (1 U/ml). The proportion of apoptotic cells (cells
with <2 N DNA content) was determined by ﬂow cytometry after propidium iodide staining. Error bars represent SEM (N= 3 biological replicates)
and p values were obtained via Student’s two-tailed t test. c Cells were cultured in the absence of EPO for 1.5 h, followed by 20 h treatment with Dox
(200 ng/ml) or DNR (0.25 µM) in the presence or absence of EPO (1 U/ml). Caspase-3 activity was measured by ﬂow cytometry. d Cells were cultured
in the absence of EPO for 1.5 h, exposed to 6 Gy γ-radiation and cultured for an additional 6 h in the presence or absence of EPO (1 U/ml) before
assessment of apoptosis by TUNEL assay. Error bars represent SEM (N= 3 biological replicates)
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Fig. 2 (See legend on next page.)
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To determine whether EPO destabilizes p53 protein,
DA3/EPOR cells were treated with cycloheximide to
inhibit protein synthesis and the amount of p53 protein in
cell extracts was measured by western blotting. Cells were
treated with DNR for 10 h in the presence or absence of
EPO. Cycloheximide was added during the last 4 h of
treatment. In the absence of EPO, p53 protein levels
remained stable in DNR-treated cells (Fig. 4c, d). In the
presence of EPO, there was a signiﬁcant destabilization of
p53 protein in DNR-treated cells. Consistent with our
ﬁnding that EPO destabilizes p53 in DNR-treated cells,
the addition of the proteasome inhibitor MG-132 com-
pletely prevented the decrease in p53 levels by EPO
(Fig. 4e). Taken together, these data indicate that EPO
destabilizes p53 protein in DNR-treated cells through the
proteasomal degradation pathway.
EPO regulates the Mdm2−p53 pathway
An important regulator of p53 protein stability is the
Mdm2 E3 ubiquitin ligase1. The stabilization of p53
protein following DNA damage is believed to result from
stress-induced modiﬁcations in p53 and Mdm2 that dis-
rupt p53-Mdm2 binding. To determine if EPO modulates
Mdm2 expression, we measured the levels of p53 and
Mdm2 protein in DA3/EPOR cells treated with DNR in
the presence or absence of EPO. There was a decrease in
Mdm2 protein levels following DNA damage and this
reduction was prevented by EPO (Fig. 5a). The reduction
of Mdm2 expression following DNA damage and the
ability of EPO to counteract this effect were conﬁrmed
with two additional antibodies directed to Mdm2
(Fig. 5b). The downregulation of Mdm2 in response to
DNA damage was reported previously and has been
attributed to enhanced Mdm2 degradation due to phos-
phorylation47,48 or epitope masking due to phosphoryla-
tion49. Uniform results with three antibodies to Mdm2
renders the second possibility less likely. The ability of
EPO to interfere with DNR-dependent Mdm2 down-
regulation and restore Mdm2 expression in DNR-treated
cells is likely to contribute to p53 protein destabilization.
In the next series of experiments, we used nutlin-3a, a
small molecule antagonist of Mdm2 that stabilizes and
activates p53 through a non-genotoxic process50. Treat-
ment of DA3/EPOR cells with nutlin-3a for 24 h elevated
p53 protein levels and decreased Mdm2 protein levels
(Fig. 5c) as was seen previously following DNR treatment.
The reduction of Mdm2 expression following nutlin-3a
treatment was conﬁrmed with two additional Mdm2
Fig. 3 EPO promotes Mcl-1 protein expression in DNR-treated cells. a DA3/EPOR cells were cultured in the absence of EPO for 6 h followed by 6
h of treatment with DNR (0.25 µM) in the presence or absence of EPO (1 U/ml). Mcl-1 protein expression was determined by western blot analysis. β-
actin levels serve as a loading control. The blot shown is representative of two independent experiments. b RT-qPCR analysis of Mcl-1 RNA. RNA was
prepared from cells treated as in (a). Ct values were normalized to 18S rRNA. Error bars represent SEM (N= 3 biological replicates). One-way ANOVA
did not return a signiﬁcant f-statistic. Control cells were cultured in complete medium and were not treated with DNR
(see ﬁgure on previous page)
Fig. 2 EPO promotes sustained arrest in G1. a Cells were cultured in the absence of EPO for 1 h followed by treatment with DNR (0.25 µM) in the
presence or absence of EPO (1 U/ml) for the times indicated. Treated cells were ﬁxed with 75% ethanol and then stained with propidium iodide prior
to analysis by ﬂow cytometry. Apoptotic populations of cells have <2 N DNA content. Representative cell cycle proﬁles are shown. b DA3/EPOR cells
were left untreated or treated with DNR (0.25 µM) in the presence or absence of EPO (1 U/ml) for 24 h. DNR was withdrawn and the cells were placed
in medium supplemented with 10% FBS and EPO (1 U/ml). At the times indicated, viable cell numbers were determined by Trypan blue staining. The
right panel shows the proportion of live cells in each of the four samples at the times indicated
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Fig. 4 EPO promotes p53 destabilization through a posttranslational mechanism. a Cells were cultured in the absence of EPO for 1 h followed
by 6 h of treatment with DNR (0.25 µM) in the presence or absence of EPO (1 U/ml). Protein expression levels were determined by western blot
analysis using the indicated antibodies. The FL393 blot was stripped and re-probed with a p21 antibody. β-actin protein levels were used as a loading
control for the FL393/p21 blot and for a separate PAb421 blot. b RT-qPCR analysis of p53 RNA reveals that p53 mRNA remained unaltered after EPO
treatment. RNA was prepared from cells treated as in (a). Ct values were normalized to 18S rRNA using the Pfafﬂ method. Error bars represent SEM
(N= 3 biological replicates). c Cells were cultured in the absence of EPO for 1 h followed by 10 h of treatment with DNR (0.25 µM) in the presence or
absence of EPO (1 U/ml). Cycloheximide (40 µg/ml) was added at the 6 h time point of treatment for a total of 4 h. Cells were harvested at the times
indicated and p53 expression was measured by western blot analysis. β-actin protein levels were used as a loading control. Protein bands were
visualized using ﬂuorochrome-conjugated secondary antibodies and detected using a Typhoon variable mode imager. The data shown are
representative of three independent experiments. d Densitometric analyses of relative p53 proteins levels were performed using the ImageJ program
and normalized to β-actin levels for each time point. Normalized p53 protein levels were then plotted as a relative value compared with normalized
p53 protein levels at 0 min after cycloheximide addition (N= 3 biological replicates). e Cells were cultured in the absence of EPO for 1 h followed by
10 h of treatment with DNR (0.25 µM) with or without EPO (1 U/ml). MG-132 (5 µM) was added at the 6 h time point for a total of 4 h. p53 protein
levels were measured by western blot analysis. A representative western blot is shown
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antibodies (Fig. 5d). Nutlin-3a induced apoptosis in a
large fraction of the cells (Fig. 5e). EPO attenuated all
these effects by nutlin-3a: Mdm2 levels were restored to
normal, p53 expression was suppressed and apoptosis was
largely prevented (Fig. 5c–e). We found that Mdm2 is
constitutively phosphorylated on Ser166 in DA3/EPOR
cells, and that EPO restored Mdm2 expression and
phosphorylation (Ser166) in both DNR-treated and
nutlin-3a-treated cells (Fig. 5a–d). Phosphorylation of
Mdm2 at Ser166 is associated with Mdm2 protein stabi-
lization in unstressed cells51. p21 protein levels increased
in response to nutlin-3a treatment and remained elevated
in cells treated with nutlin-3a and EPO (Fig. 5c) as seen
previously with DNR in Fig. 4a. The ability of EPO to
suppress nutlin-3a-mediated apoptosis and to interfere
with the nutlin-3a-mediated changes in p53 and Mdm2
levels suggests that EPO signaling regulates the Mdm2
−p53 interaction.
Fig. 5 EPO increases Mdm2 expression after DNR or nutlin-3a treatment and suppresses nutlin-3a-induced apoptosis.Western blot showing
p53 and Mdm2 protein levels in cells treated with DNR (a, b) or with nutlin-3a (c, d) in the presence or absence of EPO. In (a) and (b), DA3/EPOR cells
were cultured in the absence of EPO for 1 h followed by 10 h of treatment with DNR (0.25 µM) with or without EPO (1 U/ml). In (c) and (d), cells were
cultured in the absence of EPO for 0.5 h followed by 24 h of treatment with nutlin-3a (10 µM) with or without EPO (1 U/ml). Protein expression levels
were determined by western blot analysis using the indicated antibodies. The HDM2-323 antibody recognizes full-length MDM2 and the SMP14
antibody recognizes the MDM2 p60 cleavage product. (e) Cells were treated as in (c, d) and the proportion of cells undergoing apoptosis (cells
having <2 N DNA content) was measured by ﬂow cytometry after staining with propidium iodide
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EPO does not protect mutant p53-expressing OCI-M1 cells
from DNR-induced apoptosis
Since EPO protects against DNR-induced apoptosis in
p53 wild-type cells through a process that involves p53
destabilization, we reasoned that EPO should have no
effect on mutant p53-expressing cells. We selected the
OCI-M1 human erythroleukemia cell line to test this idea
because these cells express stable mutant p53 protein
(L145R) and EPORs36,52. We conﬁrmed that OCI-M1
cells are responsive to EPO stimulation by measuring the
phosphorylation of JAK2, the receptor-proximal effector
of EPO signaling (Fig. S2a). We then treated OCI-M1 cells
with DNR in the absence or presence of EPO and mea-
sured p53 protein levels and apoptosis. OCI-M1 cells
express high levels of mutant p53 protein that were
unaffected by DNR or EPO (Fig. S2b). Moreover, DNR-
mediated apoptosis in OCI-M1 cells was unaffected by
EPO (Fig. S2c). These results indicate that EPO does
not enhance survival of EPO-responsive, mutant
p53-expressing OCI-M1 cells.
EPO selectively modulates the expression of p53 target
genes
After p53 activation, numerous p53 target genes are
upregulated to coordinate the cellular response to stress.
The ability of EPO to reduce p53 protein levels and to
protect cells from DNR-, Dox-, γ-radiation- and nutlin-
3a-induced cell killing raises the possibility that EPO
might affect the p53 transcriptional program. For exam-
ple, low-afﬁnity consensus binding sites on p53 target
genes might not bind to p53 when p53 levels are low53.
Moreover, Mdm2, in addition to regulating p53 degra-
dation, binds to the N-terminal transcriptional activation
domain of p53 to inhibit its transcriptional activity. Mdm2
colocalizes with p53 protein on the promoters of certain
p53 responsive genes54 and hence, Mdm2 may exert a
selective inﬂuence on p53 target gene expression through
its interaction with p53 protein bound to chromatin3,55.
To investigate this possibility, we examined the expression
of three proapoptotic genes, Puma, Pidd, and Noxa, and
several noncoding RNAs (miR-34a, miR-34b/c, and
lincRNA-p21) that are transcriptional targets of p53. The
miR-34 family represses genes that are required for pro-
liferation and cell survival and ectopic expression of miR-
34 leads to growth inhibition or apoptosis56,57. lincRNA-
p21 has been shown to play a role in p53-dependent
apoptosis after DNA damage58.
Pri-miR-34a, pri-miR-34b/c, and lincRNA-p21 were
strongly induced at late times (12 h) after drug treatment
and their induction was signiﬁcantly suppressed by EPO
(Fig. 6a–c). In contrast, drug-induced expression of Puma,
Noxa, and Pidd was not signiﬁcantly affected by EPO
(Fig. 6d–f). The EPO-sensitivity of pri-miR-34a expres-
sion and EPO-insensitivity of Pidd expression after drug
treatment was conﬁrmed by northern blot analysis
(Fig. 7a–d).
EPO increases p21 expression and p53 recruitment to the
p21 promoter despite decreased p53 protein levels
Next, we examined drug-induced p21WAF1 RNA
expression. EPO inﬂuences the cellular response to p53
activation by promoting cell survival and the accumula-
tion of cells in G1; both of these processes are regulated
by p21. We had not seen an effect of EPO on p21 protein
expression after DNR treatment (Fig. 4a) or nutlin-3a
treatment (Fig. 5c). p21 mRNA was measured by northern
blotting (Fig. 7c, d) and qRT-PCR (Fig. 7e). As expected,
p21 RNA expression increased within 4 h of drug (DNR,
Dox) treatment. We observed a further increase in p21
expression when DA3/EPOR cells were treated with drug
in the presence of EPO (Fig. 7c, d). The qRT-PCR data-
conﬁrmed that cells treated with DNR and EPO
expressed more p21 RNA than cells treated with DNR
alone at the 4-h time point but not at the 8-h time point
(Fig. 7e). Taken together, these data suggest that EPO
enhances drug-induced p21 mRNA expression in DA3/
EPOR cells.
We used ChIP-qPCR to determine if EPO inﬂuenced
the recruitment of p53 to the p21 promoter in DNR-
treated DA3/EPOR cells. DA3/EPOR cells were treated
with DNR in the absence or presence of EPO for 16 h, and
then harvested for ChIP-qPCR (Fig. 8a). p53 enrichment
at the p21 promoter was normalized to total p53 protein
levels in each sample. p53 protein was present at the p21
promoter under nonstress conditions and this basal level
of p53 at the promoter did not change in cells treated with
EPO alone or with DNR alone. This is consistent with
previous reports showing that p53 is present on target
promoters in unstressed cells and becomes tran-
scriptionally active only after stress stimulation59. We
found a signiﬁcant increase in p53 recruitment to the p21
promoter in cells treated with DNR and EPO compared
with cells treated with EPO alone or DNR alone.
EPO promotes a senescence-like state
We have shown that cells treated with EPO and DNR
are viable, do not proliferate, express sustained elevated
levels of p21WAF1, and accumulate in the G1 phase of the
cell cycle. This is reminiscent of cellular senescence, a
process associated with aging in which cells enter a state
of permanent cell cycle arrest. To investigate the possi-
bility that cells treated with DNR and EPO enter a
senescence-like state, we examined senescence-associated
β-galactosidase (SAβgal) activity, a widely used senes-
cence biomarker60. As expected, we noticed fewer sur-
viving cells remaining after DNR treatment compared
with the untreated control cells. We found positive
SAβgal staining in the remaining DNR-treated cells
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(Fig. 8b) consistent with previous studies showing that
cancer cells can undergo senescence in response to
treatment with selected anticancer compounds or radia-
tion in a process known as therapy-induced senescence61.
SAβgal staining was detected in nearly all cells treated
with DNR and EPO but not in the untreated control cells
(Fig. 8b).
Discussion
In this study, we show that EPO promotes the survival
of DA3/EPOR myeloid leukemia cells treated with
genotoxic and nongenotoxic agents. The ability of EPO
to promote survival has been attributed to various
processes including EPOR upregulation62, JAK2 kinase
activation13,15,29, PI3K/Akt pathway activation62,63, Erk
Fig. 6 EPO selectively modulates the expression of DNR-induced p53 target genes. Real-time PCR (qRT-PCR) analysis of p53 target gene
expression in DA3/EPOR cells treated with DNR (0.25 μM) in the presence or absence of EPO (1 U/ml) for different periods. Cells were cultured in the
absence of EPO for 1 h followed by treatment with DNR with or without EPO. Ct values were normalized to control 18S rRNA using the Pfafﬂ method.
Error bars represent SEM (N= 3 biological replicates). Statistical analysis of the results was evaluated by one-way ANOVA followed by Tukey’s HSD
post hoc test
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phosphorylation30,64,65, Bim phosphorylation and
degradation66, GSK-3β downregulation62 and expres-
sion of antiapoptotic proteins67–69. Many of these EPO-
dependent changes are cell type-speciﬁc. The ability of
EPO to activate several intracellular signaling pathways
downstream of EPOR ligation that individually promote
survival may explain the widespread protective effects of
EPO on various tissues and cells.
Fig. 7 EPO selectively modulates the expression of drug-induced p53 target genes. a Northern blot analysis showing pri-/pre-miR-34a
expression in DA3/EPOR cells treated with Dox (200 ng/ml) or DNR (0.25 µM) in the presence or absence of EPO. U6 served as the loading control for
miR-34a. b Relative abundance of pri-/pre-miR-34a was determined by phosphor-image analysis after normalizing to the level of U6 mRNA in each
sample. c Northern blot analysis showing Pidd and p21 mRNA expression in DA3/EPOR cells treated with Dox (200 ng/ml) or DNR (0.25 µM) in the
presence or absence of EPO (1 U/ml). The same ﬁlter was hybridized sequentially and GAPDH served as the loading control. d Relative abundance of
Pidd and p21 expression was determined by phosphor-image analysis after normalizing to the level of GAPDH mRNA in each sample. e qRT-PCR
analysis of p21 mRNA expression in DA3/EPOR cells. Cells were cultured in the absence of EPO for 1 h followed by treatment with Dox (200 ng/ml) or
DNR (0.25 µM) with or without EPO (1 U/ml) for 4 and 8 h. Ct values were normalized to 18S rRNA using the Pfafﬂ method. Error bars represent SEM
(N= 3 biological replicates) and p values were obtained via one-way ANOVA followed by Tukey’s HSD post hoc test
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We ﬁnd that EPO destabilizes p53 protein after DNR
and nutlin-3a treatment. Moreover, we show a correlation
between p53 and Mdm2 expression. DNR and nutlin-3a
enhance p53 protein expression and decrease Mdm2
expression. EPO counteracts these effects of DNR and
nutlin-3a resulting in decreased p53 protein levels and
increased Mdm2 protein levels. Nutlin-3a treatment was
initially shown to increase the level of Mdm2 protein
expression50 in contrast to what we see in DA3/EPOR
cells. We conﬁrmed the downregulation of Mdm2
expression following nutlin-3a or DNR treatment using
three different antibodies directed to Mdm2. It is possible
that Mdm2-nutlin-3a complexes exhibit different stability
in different cell types. Our ﬁndings suggest a model in
which EPO promotes survival of DA3/EPOR cells after
treatment with genotoxic and nongenotoxic agents in part
through increased Mdm2-dependent degradation of wild-
type p53 protein.
In addition, we ﬁnd that DNR reduces the level of the
antiapoptotic Mcl-1 protein and that EPO restores Mcl-1
protein expression in cells treated with DNR. Mcl-1 is an
unstable protein with a short half-life and its expression is
regulated by various growth factors. The degradation of
Mcl-1 in response to various DNA-damaging agents is
considered to be an important early event in apopto-
sis43,45. We suggest that both the upregulation of Mcl-1
expression and the downregulation of p53 expression may
contribute to the prosurvival function of EPO in drug-
treated cells.
We ﬁnd that EPO selectively inﬂuences p53 target gene
expression. EPO enhances p21 expression, represses the
expression of pri-miR34a, pri-miR34b/c and lincRNA-
p21, and has no effect on drug-induced Pidd, Puma and
Noxa expression. The repression of pri-miR-34a and pri-
miR-34b/c cannot be attributed to enhanced degradation
of these ncRNAs since both were found to be stable in
DNR-treated DA3/EPOR cells and EPO had no effect on
pri-miRNA half-life when the DNR-treated cells were
maintained in medium containing actinomycin D for 8 h
to inhibit transcription (data not shown).
We do not know if the changes in p53 target gene
expression resulting from EPO treatment contribute to
EPO-mediated cell survival or are a consequence of EPO
treatment. For example, we cannot exclude the possibility
that the suppression of pri-miR-34a, pri-miR34b/c, and
lincRNA-p21 in response to EPO treatment reﬂects the
accumulation of cells in the G1 phase of the cell cycle. In
one recent study, various human cells were sorted by
ﬂuorescence-activated cell sorting and miRNA expression
was found to be stable throughout the cell cycle70. No
common pattern of ncRNA expression during the cell
cycle has emerged71,72.
We have shown that cells treated with EPO and DNR
enter a senescence-like state. Recent studies show that
senescent cells acquire a senescent-associated secretory
phenotype (SASP), which involves the secretion of
proinﬂammatory cytokines that promote cancer progres-
sion73. In a mouse breast cancer model, Jackson et al.
reported that p53 wild-type tumors, unlike mutant p53
tumors, undergo senescence in response to chemother-
apy, avoiding abnormal mitoses and cell death74. The
senescent tumor cells acquired an SASP that could induce
proliferation in neighboring, nonsenescent cells. The
tumor cells of cancer patients receiving chemotherapy or
radiation treatment will undergo excessive stress leading
to cell death or senescence. The administration of ESAs to
control chemotherapy-induced anemia could redirect the
cellular stress response towards senescence and tumor
cell survival, especially in p53 wild-type tumors. Senescent
cells could exert deleterious effects on the tissue micro-
environment through the secretion of proinﬂammatory
cytokines and could contribute to tumor progression and
Fig. 8 EPO enhances recruitment of p53 to the p21 promoter and
sustains a senescence-like state. a Chromatin immunoprecipitation
coupled with quantitative PCR (ChIP-qPCR) was used to evaluate p53
binding to the p21 promoter. Cells were cultured in the absence of
EPO for 1 h followed by 16 h of treatment with DNR (0.25 μM) in the
presence or absence of EPO (1 U/ml). Ct values were normalized to
non-IP input and p53 levels for each sample, and are expressed as
Enrichment (% input). Error bars represent SEM (N= 3 biological
replicates) and p values were obtained from one-way ANOVA
followed by Tukey’s HSD post hoc test. b DA3/EPOR cells were treated
with DNR in the presence or absence of EPO for 24 h. The cells were
then washed to remove DNR and placed in drug-free medium
containing 10% FBS and EPO for an additional 24 h prior to staining
for SAβgal as described60. Control cells were cultured in complete
medium and were not treated with DNR. The images were taken at
×200 magniﬁcation
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clinical relapse. Our ﬁndings speak to the safety concerns
related to the use of ESAs to treat cancer-associated
anemia.
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